Vergelijking

Amycretin vs. VK2735

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Amycretin	VK2735
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Amycretin

Volledige vermelding →

VK2735

Volledige vermelding →

Frequently asked questions

What is the difference between Amycretin and VK2735?: Amycretin is classified as "Metabool", while VK2735 is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or VK2735?: The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and VK2735 in Germany and the United States?: Duitsland: Amycretin — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

VK2735

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Amycretin and VK2735?

Amycretin is classified as "Metabool", while VK2735 is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or VK2735?

The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and VK2735 in Germany and the United States?

Duitsland: Amycretin — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.